Single rod subdermal implant: acceptance and problems associated with it at a tertiary care centre in Southern Rajasthan
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20242824Keywords:
Contraception, Implant, Implanon, Family planningAbstract
Background: The government of India expanded the contraceptive basket under national family planning program by the inclusion of subdermal contraceptive implants (single rod) in the year 2023. In our institute, RNT medical college and attached hospitals, Udaipur, the insertion and use of the implant, after adequate training sessions, began in September 2023. Since then, there has been slow, but sure acceptance of the Implant as a contraceptive. This study aims to provide demographic data of its users, data of the follow up, and the problems encountered by users as well as data on early removal of implant and the reasons for it.
Methods: This is a prospective cohort study, conducted at the department of obstetrics and gynaecology at RNT medical college and attached hospitals, Udaipur. Study conducted from September 2023 to July 2024 time period.
Results: The implant was introduced in our institute as a contraception option in September 2023. No particular trend could be detected with regard to numbers of insertion of the implant. The mean age of the users is 27.9±11.3 years, with majority of its users belonging to the age group of 25-29 years and maximum number of insertions happened immediately post-partum, before the patient was discharged from hospital. The mean number of living children was 2. A majority of women had 2 living children at the time of insertion (regardless of parity).
Conclusions: Large number of women are accepting of the implant as a method of contraception. From our findings, limited though they may be, we conclude that the average user of the implant is a woman between 25-29 years of age with two living children. The biggest problem, we face at present, is lack of follow up.
References
Office of the Registrar General and Census Commissioner (India). India Sample Registration System Statistical Report 2020. New Delhi: Office of the Registrar General and Census Commissioner (India). 2022.
Joshi B, National Institute for Research in Reproductive Health, Indian Council of Medical Research. Health Technology Assessment of Long-acting Reversible Contraceptives in India. New Delhi: HTAIn. 2018.
Bennink HJ. The pharmacokinetics and pharmacodynamics of Implanon, a single-rod etonogestrel contraceptive implant. Eur J Contracept Reprod Health Care. 2000;5(2):12-20.
Warren C, Cox M, Hughes R, Schreiber C. Etonogestrel implant (Implanon) for contraception: a systematic review. Contraception. 2010;81(3):220-30.
Shiferaw M, Kassahun W, Zawdie B. Anthropometric indices, blood pressure, and lipid profile status among women using progestin-only contraceptives: comparative cross-sectional study. BMC Women's Health. 2021;21:34.
Moray KV, Chaurasia H, Sachin O. A systematic review on clinical effectiveness, side-effect profile and meta-analysis on continuation rate of etonogestrel contraceptive implant. Reprod Health. 2021;18(1):4.
Brito MB, Ferriani RA, Quintana SM, Diogenes Yazlle MEH, De Sá MFS, Vieira CS. Safety of etonogestrel contraceptive implant during breastfeeding: a randomized controlled trial. The Lancet. 2007;370(9601):295-302.
Varney SJ, Guest JF. Relative cost effectiveness of Depo-Provera, Implanon, and Mirena in reversible long-term hormonal contraception in the U.K. Pharmacoeconomics.2004;22(17):1141-51.
AMCP Dossier for Implanon. Roseland, NJ: Organon USA, Inc. 2006.
Agrawal A, Robinson C. Spontaneous snapping of an Implanon in two halves in situ. J Fam Plann Reprod Health Care. 2003;29:238.
Lakha F, Glasier AF. Continuation rates of Implanon in the UK: data from an observational study in a clinical setting. Contraception. 2006;74:287-9.
Gezginc K, Belci O, Karatayli R, Colakoglu MC, Colakoglu MC. Contraceptive efficacy, side effects of implanon(R) Eur J Contracep Reprod Health Care. 2007;12:362-5.
WHO Model Lists of Essential Medicines. Available at: http://www.who.int/groups/expert-committee-on-selection-and-use-of-essentialmedicines/essential-medicines-lists. Accessed on 12 January, 2024
Jain R, Muralidhar S. Contraceptive methods: needs, options and utilization. J Obstet Gynaecol India. 2011;61(6):626-34.
Joshi R, Khadilkar S, Patel M. Global trends in use of long-acting reversible and permanent methods of contraception: seeking a balance. Int J Gynaecol Obstet. 2015;131(1):S60-63.
Arora N, Choudhary S, Raghunandan C. Young women opting for tubal sterilization in rural India: reasons and implications. J Obstet Gynaeco. 2010;30(2):175-8.
